Subtype
Lung Small Cell Carcinoma
CI-CAN-00005832SCLCExplore in graph →
381 active trials6 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005832SCLCExplore in graph →
Clinical trials
1,100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (157)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01417806 | Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer | unknown | Phase 2 | 28 | South Florida Veterans Affairs Foundation for Research and EducationFED | 1 | Aug 16, 2011 | clinicaltrials |
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer | terminated | Phase 2 | 43 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 |
| clinicaltrials |
| NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | completed | Phase 2 | 34 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT00403403 | A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Apr 29, 2011 | clinicaltrials |
| NCT00178698 | Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors(FR-WB-TT/che) | unknown | Phase 2 | 36 | The University of Texas Health Science Center, HoustonOTHER | 1 | Mar 3, 2011 | clinicaltrials |
| NCT00156286 | Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC | completed | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 16, 2010 | clinicaltrials |
| NCT01222936 | LBH Phase II in Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 21 | Southern Europe New Drug OrganizationOTHER | 2 | Oct 18, 2010 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00308529 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 55 | SCRI Development Innovations, LLCOTHER | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00494026 | Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 20, 2009 | clinicaltrials |
| NCT00447421 | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | terminated | Phase 1 / Phase 2 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2009 | clinicaltrials |
| NCT00319969 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | completed | Phase 2 | 76 | Celgene CorporationINDUSTRY | 1 | Sep 30, 2009 | clinicaltrials |
| NCT00475657 | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer | terminated | Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2009 | clinicaltrials |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma | terminated | Phase 2 | 50 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 30, 2009 | clinicaltrials |
| NCT00116610 | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | completed | Phase 2 | 75 | Poniard PharmaceuticalsINDUSTRY | 3 | Jan 21, 2009 | clinicaltrials |
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide(SESAME) | completed | Phase 2 / Phase 3 | 432 | SanofiINDUSTRY | 14 | Dec 23, 2008 | clinicaltrials |
| NCT00546130 | Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer(RNCLC) | unknown | Phase 2 | 45 | University of ToyamaOTHER | 1 | Sep 3, 2008 | clinicaltrials |
| NCT00298688 | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 56 | AstraZenecaINDUSTRY | 2 | Jun 12, 2008 | clinicaltrials |
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 24 | Swedish Medical CenterOTHER | 1 | Apr 5, 2007 | clinicaltrials |
| NCT00168922 | Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Apr 27, 2006 | clinicaltrials |
| NCT00168896 | A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage | unknown | Phase 2 / Phase 3 | 286 | Charite University, Berlin, GermanyOTHER | 1 | Feb 14, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Aug 16, 2011source: clinicaltrials